| NANOVIRICIDES, INC. |
|---------------------|
| Form 10-Q/A |
| February 25, 2015 |

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended: December 31, 2014

Commission File Number: 001-36081

NANOVIRICIDES, INC.

(Exact name of Company as specified in its charter)

<u>NEVADA</u> 76-0674577

(State or other jurisdiction) (IRS Employer Identification No.)

of incorporation or organization)

135 Wood Street, Suite 205

West Haven, Connecticut 06516

(Address of principal executive offices and zip code)

| (203) 937-6137 |
|--|
| (Company's telephone number, including area code) |
| |
| Indicate by check mark whether the Company (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Company was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No " |
| Indicate by check mark whether the Company has submitted electronically and posted on its corporate web site, if |
| any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Company was required to submit and post such files). Yes x No " |
| |
| Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. |
| |
| Large accelerated filer "Accelerated filer " Non-accelerated filer x Smaller reporting company " |
| Indicate by check mark whether the Company is a shell company (as defined in Rule 12b-2 of the Exchange Act). |
| Yes "No x |
| |
| The number of shares outstanding of the Company's Common Stock as of February 24, 2015 was approximately: 56,564,190. |

Explanatory Note

The sole purpose of this Amendment to NanoViricides, Inc.'s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2014, originally filed with the Securities and Exchange Commission on February 24, 2015 (the "Form 10-Q"), is to provide the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language) to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL. No other changes have been made to the Form 10-Q.

ITEM 6. EXHIBITS.

(a) Exhibit index

Exhibit Number Description of Exhibits

| 31.1 | Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Executive Officer * |
|---------|---|
| 31.2 | Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Financial Officer * |
| 32.1 | Section 1350 Certification of Chief Executive Officer * |
| 32.2 | Section 1350 Certification of Chief Financial Officer * |
| 101.INS | XBRL Instance Document** |
| 101.SCH | XBRL Taxonomy Extension Schema Document** |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document** |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document** |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document** |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document** |

These exhibits were previously included or incorporated by reference in NanoViricides, Inc.'s Quarterly Report on *Form 10-Q for the fiscal quarter ended December 31, 2014, filed with the Securities and Exchange Commission on February 24, 2015.

^{**}Filed herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NANOVIRICIDES, INC.

/s/ Eugene Seymour, M.D.

Dated: February 25, 2015 Name: Eugene Seymour, M.D.

Title: Chief Executive Officer and Director

(Principal Executive Officer)

/s/ Meeta Vyas

Dated: February 25, 2015 Name: Meeta Vyas

Title: Chief Financial Officer

(Principal Financial Officer)

EXHIBIT INDEX

Exhibit Number Description of Exhibits

| 31.1 | Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Executive Officer* |
|---------|--|
| 31.2 | Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Financial Officer* |
| 32.1 | Section 1350 Certification of Chief Executive Officer* |
| 32.2 | Section 1350 Certification of Chief Financial Officer* |
| 101.INS | XBRL Instance Document** |
| 101.SCH | XBRL Taxonomy Extension Schema Document** |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document** |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document** |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document** |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document** |

These exhibits were previously included or incorporated by reference in NanoViricides, Inc.'s Quarterly Report on *Form 10-Q for the fiscal quarter ended December 31, 2014, filed with the Securities and Exchange Commission on February 24, 2015.

^{**}Filed herewith.